Publications by authors named "Gabriele Elser"

Claim this Profile
I
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observations.
Pauline Wimberger, Jacobus Pfisterer, Andreas du Bois, Felix Hilpert, Markus Kerkmann, Gabriele Elser

Eur J Surg Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.
Dominik Denschlag, Bastian Czogalla, Florian Heitz, Markus Kerkmann, Laura-Christin Fangmann, Gabriele Elser

Geburtshilfe Frauenheilkd· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group.
Pauline Wimberger, Jacobus Pfisterer, Andreas du Bois, Felix Hilpert, Markus Kerkmann, Gabriele Elser

Int J Gynecol Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Philipp Harter, Jan Hauke, Florian Heitz, Alexander Reuss, Stefan Kommoss, Gabriele Elser

PLoS One· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.
David J Pulford, Philipp Harter, Anne Floquet, Catherine Barrett, Dong Hoon Suh, Gabriele Elser

BMC Med Ethics· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Philipp Harter, Jalid Sehouli, Rainer Kimmig, Jörn Rau, Felix Hilpert, Gabriele Elser

Invest New Drugs· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.
Ignace Vergote, Gabriele Elser, Benedicte Votan, Laura Farrelly, Joke De Roover

Int J Gynecol Cancer· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis